Summary
The rapid adoption of artificial intelligence (AI) raises challenges related to ethics, safety, equity, and governance that require robust regulatory frameworks. In most jurisdictions, AI-driven medical devices are already covered by existing medical device frameworks, although new AI-specific legislation may be required to address the challenges posed by recent advancements. This expert review focuses on frameworks and legislation explicitly tailored to AI, synthesizing research literature, government and intergovernmental framework programs, and online media coverage to provide an up-to-date assessment of global AI-specific regulation or strategies in healthcare as of December 2024. Our findings show that only 15.2% (n=30/197) of countries or territories have enacted legally binding AI-specific legislation, including the 27 member states of the European Union (EU) following the adoption of the EU AI Act. A further 9.1% (n=18/197) have drafted legislation, and 28.4% (n=56/197) have issued non-binding guidelines. Notably, 47.2% (n=93/197) of countries or territories do not have an AI-specific framework or legislation in place. Furthermore, our results highlight disparities between the Global North and South, with 60.3% (n=82/136) of Global South countries or territories lacking frameworks or legislation, compared to 18% (n=11/61) in the Global North. In conclusion, our work provides an overview of the status quo of AI regulation around the world, highlights disparities in the adoption of frameworks and legislation, and calls for the need for intergovernmental and regional cooperation.
Competing Interest Statement
Outside the submitted work, the authors declare the following competing interests: Keno K Bressem reports grants from the European Union (101079894), the Wilhelm Sander Foundation, the Bundesministerium für Bildung und Forschung (BMBF), the Else Kröner Foundation, Bayern Innovativ, and the Max Kade Foundation; Keno K Bressem reports speaker fees from Canon Medical Systems Corporation and GE Healthcare; Keno K Bressem is a member of the advisory board of the EU Horizon 2020 LifeChamps project (875329) and the EU IHI project IMAGIO (101112053); Daniel Truhn holds stocks in StratifAI GmbH and Synagen GmbH; Stephen Gilbert reports grants from the Horizon Europe Program as part of the projects ASSESS-DHT (101137347) and CYMEDSEC (101094218) and funding through a BMBF project (Personal Mastery of Health & Wellness Data, PATH) on consent in health data sharing, financed through the European Union NextGenerationEU program; Stephen Gilbert reports nonfinancial interest as an Advisory Group member of the EY-coordinated "Study on Regulatory Governance and Innovation in the field of Medical Devices" conducted on behalf of the DG SANTE of the European Commission. Stephen Gilbert is the coordinator of a BMBF project (Personal Mastery of Health & Wellness Data, PATH) on consent in health data sharing, financed through the European Union NextGenerationEU program; Stephen Gilbert declares the following competing financial interests: he has or has had consulting relationships with Una Health GmbH, Lindus Health Ltd., Flo Ltd., Thymia Ltd, FORUM Institut für Management GmbH, High-Tech Gründerfonds Management GmbH, Prova Health Ltd, DG R&I of the European Commission and Ada Health GmbH and holds stock options in Ada Health GmbH; Jakob Nikolas Kather declares consulting services for Owkin, France; DoMore Diagnostics, Norway; Panakeia, UK, and Scailyte, Switzerland; Jakob Nikolas Kather holds stocks in Kather Consulting and StratifAI GmbH and has received honoraria for lectures and advisory board participation by AstraZeneca, Bayer, Eisai, MSD, BMS, Roche, Pfizer and Fresenius. None of the other authors declares potential conflicts of interest.
Funding Statement
This work is supported by the European Union under the Horizon Europe Program as part of the projects CYMEDSEC (101094218), ASSESS-DHT (101137347), and COMFORT (101079894). Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union. The European Union cannot be held responsible for them. The funding had no role in the study design, data collection and analysis, manuscript preparation, or decision to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The generated dataset, including AI-specific frameworks and legislation for 197 countries and territories, will be made publicly available under the Creative Commons Attribution 4.0 International (CC-BY-4.0) license on figshare (https://figshare.com) upon acceptance of the publication. The digital object identifier will be provided upon acceptance of the publication.
